Here's our mTNBC ICI's: In a 4-year overall
Post# of 157714
(Total Views: 692)
Posted On: 08/26/2025 5:15:21 AM
Here's our mTNBC ICI's:
In a 4-year overall survival follow-up, 5 of the patients with upregulated PD-L1 detected by LifeTracDx® blood test and treated with the ICIs atezolizumab or pembrolizumab were alive after four years. May 30th, 2025
https://www.biospace.com/press-releases/clini...ast-cancer
Google:
* The owner of the drug atezolizumab (under the brand name Tecentriq) is Genentech, a biotechnology company that is a member of the Roche Group.
* Pembrolizumab, marketed under the brand name Keytruda, is owned by Merck & Co.,
__
Dr. J just said submitting a ICI protocol on our CRC trial. Two great companies who without a doubt, in my mind at least, are working our trial & will become involved with Leronlimab --- in some way.
An LL / ICI combo includes worlds top selling drug --- Keytruda.
Outstanding headline news is coming....
"Head to open waters"
In a 4-year overall survival follow-up, 5 of the patients with upregulated PD-L1 detected by LifeTracDx® blood test and treated with the ICIs atezolizumab or pembrolizumab were alive after four years. May 30th, 2025
https://www.biospace.com/press-releases/clini...ast-cancer
Google:
* The owner of the drug atezolizumab (under the brand name Tecentriq) is Genentech, a biotechnology company that is a member of the Roche Group.
* Pembrolizumab, marketed under the brand name Keytruda, is owned by Merck & Co.,
__
Dr. J just said submitting a ICI protocol on our CRC trial. Two great companies who without a doubt, in my mind at least, are working our trial & will become involved with Leronlimab --- in some way.
An LL / ICI combo includes worlds top selling drug --- Keytruda.
Outstanding headline news is coming....
"Head to open waters"
(7)
(0)